Pharma BD Deal Intelligence
A win with a built-in exit ramp: GSK's $13B buyout of Novartis's 36.5% JV stake handed it full control of Sensodyne, Panadol, and Nicotinell, cleanly setting up the Haleon spinoff rather than leaving consumer health stranded as a permanent minority-owned drag.
GSK acquired Novartis's 36.5% stake in consumer healthcare JV for $13B.
GlaxoSmithKline agreed to acquire Novartis 36.5% stake in their shared consumer healthcare joint venture for $13 billion, taking full control of the business.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GSK acquired Novartis's 36.5% stake in consumer healthcare JV for $13B.
GSK completed $13B acquisition of Novartis 36.5% stake in consumer healthcare JV, gaining full ownership of Sensodyne, Panadol, Voltaren.
GSK combined consumer health with Pfizer division, creating ~$12.7B JV (GSK 68%, Pfizer 32%).
GSK demerged consumer health as Haleon on LSE. Biggest European listing in a decade.
Haleon FY2022 revenue GBP 10.4B, up from GBP 9.2B in 2021. Margins tracking toward mid-20s.
Acquiring Novartis stake enabled GSK to spin off Haleon at $36B+ valuation, crystallizing significant value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GlaxoSmithKline plc / Novartis Consumer Healthcare JV (this deal) | 2018 | $13.0B | 74 |
| GlaxoSmithKline plc / Theravance, Inc. | 2012 | $213M | 82 |
| GlaxoSmithKline plc / Tesaro Inc. | 2018 | $5.1B | 79 |
| GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) | 2018 | $12.7B | 76 |
| GlaxoSmithKline plc / ID Biomedical Corporation | 2005 | $1.4B | 64 |
| GlaxoSmithKline plc / Vir Biotechnology Inc. | 2020 | $595M | 51 |
| GlaxoSmithKline plc / Reliant Pharmaceuticals Inc. | 2007 | $1.6B | 47 |
← Browse all deals · How we score deals
More: 2018 deals · GlaxoSmithKline plc deals · Multiple (undisclosed) deals